Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies

NCT01799889 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

326

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor's decision to discontinue development of entospletinib.

Conditions

Chronic Lymphocytic Leukemia
Mantle Cell Lymphoma
Diffuse Large B-cell Lymphoma
Non-FL Indolent Non-Hodgkin's Lymphoma
Follicular Lymphoma

Interventions

DRUG: Entospletinib MM
DRUG: Entospletinib SDD

Sponsor

Gilead Sciences